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ReportBACE1 Deficiency Rescues Memory
Deficits and Cholinergic Dysfunction
in a Mouse Model of Alzheimer’s Disease
less of the form, size, and solubility of A polymers, a
large body of evidence suggests that A plays a causal
role in AD pathophysiology.
Amyloid precursor protein (APP) transgenic mice re-
capitulate many aspects of AD pathology including A
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amyloidosis and related cognitive deficits and are thus2 Department of Cell and Molecular Biology
used to evaluate novel therapeutic interventions for ADNorthwestern University Feinberg School
(Ashe, 2001; Janus and Westaway, 2001; Wong et al.,of Medicine
2002). Although these mouse models allow us to gatherChicago, Illinois 60611
much evidence in support of the amyloid hypothesis,3 Mayo Clinic Jacksonville
rigorous in vivo demonstration that A is directly respon-Jacksonville, Florida 32224
sible for AD-associated cognitive impairment has been4 Department of Neuroscience
difficult to obtain. For example, in mice overexpressingAmgen Inc.
mutant APP transgenes, it has not been possible toThousand Oaks, California 91320
unequivocally prove whether transgene-dependent mem-
ory deficits are due to excessive cerebral A generation
or mutant APP overexpression. Some of the recent A
immunization studies showing behavioral improvementSummary
in APP transgenic mice suggest that Amay be deleteri-
ous to memory, but the mechanisms underlying the ef--site APP cleaving enzyme 1 (BACE1) is the -secre-
fects of A immunization are not fully understood (Dodeltase enzyme required for generating pathogenic
et al., 2003; Schenk, 2002; Selkoe and Schenk, 2003).-amyloid (A) peptides in Alzheimer’s disease (AD).
A is proteolytically generated from APP by the se-BACE1 knockout mice lack A and are phenotypically
quential action of two enzymes, the - and -secretasesnormal, suggesting that therapeutic inhibition of BACE1
(Hardy and Selkoe, 2002; Selkoe and Schenk, 2003;may be free of mechanism-based side effects. How-
Turner et al., 2003; Vassar and Citron, 2000). BACE1 hasever, direct evidence that BACE1 inhibition would
been identified as a membrane bound aspartyl proteaseimprove cognition is lacking. Here we show that BACE1
that fulfills all known criteria for -secretase (Hussain etnull mice engineered to overexpress human APP
al., 1999; Lin et al., 2000; Sinha et al., 1999; Vassar et(BACE1/·Tg2576) are rescued from A-dependent
al., 1999; Yan et al., 1999) and thus is a prime therapeutichippocampal memory deficits. Moreover, impaired
target (Citron, 2002; Selkoe and Schenk, 2003; Wolfe,hippocampal cholinergic regulation of neuronal excit-
2002). Although the development of potent and specificability found in the Tg2576 AD model is ameliorated
small-molecule BACE1 inhibitors is being vigorouslyin BACE1/·Tg2576 bigenic mice. The behavioral and
pursued (Citron, 2002; John et al., 2003; Tang et al.,electrophysiological rescue of deficits in BACE1/·
2003), pharmacological strategies for inhibiting -secre-Tg2576 mice is correlated with a dramatic reduction
tase in vivo are currently lacking.of cerebral A40 and A42 levels and occurs before
We have taken a gene-targeting approach to deter-amyloid deposition in Tg2576 mice. Our gene-based
mine the therapeutic potential of BACE1 inhibition forapproach demonstrates that lower A levels are bene-
ameliorating AD-associated cognitive deficits and to rig-ficial for AD-associated memory impairments, validat-
orously test the amyloid cascade hypothesis in an ining BACE1 as a therapeutic target for AD.
vivo model of AD. Knocking out the BACE1 gene in mice
abrogates the formation of cerebral A and amyloid
Introduction deposits, and the mice remain healthy, fertile, and have
no obvious neurological abnormalities (Cai et al., 2001;
In its original conception, the amyloid cascade hypothe- Luo et al., 2001, 2003; Roberds et al., 2001). These re-
sis postulates that amyloid plaques, composed of de- sults suggest that BACE1 inhibition is a valid therapeutic
posited aggregates of the -amyloid (A) peptide, are strategy for AD and may not encounter severe mecha-
central to the pathogenesis of Alzheimer’s disease (AD) nism-based toxicity. In this study, we crossed BACE1
(Hardy and Selkoe, 2002; Selkoe and Schenk, 2003; null mutant (BACE1/) mice (Luo et al., 2001) with trans-
Turner et al., 2003). However, recent studies have begun genic mice that overexpress human APP-695 with the
to implicate small soluble assemblies of A peptides as Swedish familial mutation (Tg2576) (Hsiao et al., 1996).
potential neurotoxic species in AD (Dodart et al., 2002; We demonstrate that reduction of A levels by BACE1
Hardy and Selkoe, 2002; Selkoe, 2002; Walsh et al., gene deletion can prevent learning and memory impair-
2002), and thus the amyloid cascade hypothesis has ment and hippocampal cholinergic dysfunction in the
been broadened to include so-called A-derived diffus- Tg2576 model of AD. Since BACE1/·Tg2576 bigenic
ible ligands (ADDLs) and protofibrils of A (Gong et al., mice still overexpress mutant APP, we conclude that
2003; Hartley et al., 1999; Lambert et al., 1998). Regard- excess A, rather than APP overexpression, is directly
responsible for the cognitive and electrophysiological
abnormalities found in Tg2576 monogenic mice. These*Correspondence: ohno@northwestern.edu (M.O.), r-vassar@
northwestern.edu (R.V.), jdisterhoft@northwestern.edu (J.F.D.) results strongly support the amyloid cascade hypothe-
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sis and show for the first time the beneficial effects of BACE1/·Tg2576 bigenic mice (p  0.01). In contrast
to social recognition, the BACE1 null mutation by itselfBACE1 (-secretase) inhibition on AD-associated cogni-
tive deficits. moderately but significantly affected spontaneous alter-
nation behavior (p  0.05). The total number of arm
entries in the alternation Y maze test, a measure ofResults
exploratory activity, was increased [F(3,68)  5.83, p 
0.01] both in BACE1/ monogenic (p  0.05) and inRescue of Memory Deficits
BACE1/·Tg2576 bigenic mice (p  0.01) (Figure 1C).in BACE1/·Tg2576 Mice
This increased level of exploration is not likely to beRecent studies have focused on soluble A assemblies,
responsible for the impaired alternation performance ofrather than insoluble A fibrils, as potential pathogenic
BACE1/ mice, since BACE1/·Tg2576 mice werefactors in AD (Dodart et al., 2002; Lambert et al., 1998;
normal in spontaneous alternation behavior even thoughSelkoe, 2002; Walsh et al., 2002). Moreover, some as-
they also exhibited increased exploration.pects of the behavioral phenotypes of Tg2576 mice pre-
cede amyloid plaque formation (beginning at 9–12
Reduction in Cerebral A Improves Memorymonths of age) (Dineley et al., 2002; Holcomb et al.,
in BACE1/·Tg2576 Mice1998; Westerman et al., 2002). It has been unclear from
After memory testing, sandwich ELISA assays were per-these studies whether the memory deficits of APP trans-
formed to correlate genotypes and behavioral pheno-genic mice result from excessive A or APP overexpres-
types with A levels in the brain. Consistent with oursion in the brain. To address these questions, we tested
previous results (Luo et al., 2001), cerebral AgenerationTg2576, BACE1/·Tg2576 bigenic, BACE1/ mono-
was nearly abolished in the BACE1/·Tg2576 bigenicgenic, and wild-type littermates at 4–6 months of age,
mice as compared with Tg2576 mice [A40, F(1,10) when Tg2576 mice lack histologically visible amyloid
175.09, p 0.01; A42, F(1,10) 89.50, p 0.01] (Tableplaques but have high cerebral A levels (Kawaraba-
1). A40 and A42 ELISA values of BACE1/·Tg2576yashi et al., 2001).
were only1% and 5%, respectively, of Tg2576 val-First, we analyzed mice with a hippocampus-depen-
ues, and were similar to A values found in wild-typedent social recognition task (Kogan et al., 2000), which
brain (3% and 5%, respectively). The origin of thetests the ability of mice to identify and remember con-
A signals in BACE1/·Tg2576 samples is unclear,specifics (specific details of an individual) and relies
although we suspect that the signals derive from Amostly on olfaction in rodents (Ferguson et al., 2002).
species starting at positions other than Asp1 gener-In this task, a repeated exposure to the same juvenile
ated by unidentified proteases. Alternatively, BACE1/·results in decreased duration of investigation behavior,
Tg2576 A ELISA signals may result from antibodyand thus the difference in investigation time between
cross-reactivity to A-containing APP fragments ratherthe first and second exposure can be used as an index
than to A species. Nevertheless, our data indicates thatof social recognition memory (Ferguson et al., 2002).
reduction of cerebral A to wild-type levels underlies theThe investigation times during the first exposure trial
memory improvement in BACE1/·Tg2576 mice.were not significantly different between the four groups
We also found that BACE1/ monogenic brain hadtested [ANOVA F(3,64)  1.42, p  0.25; wild-type,
significantly lower levels of A40 [F(1,12)  68.07, p 48.5  3.3 s, mean  SEM, n  20; BACE1/, 52.3 
0.01] and A42 [F(1,12)  85.44, p  0.01] as compared4.7 s, n  19; Tg2576, 43.5  4.5 s, n  19;
with wild-type brain (Table 1). Thus, BACE1/ mutantsBACE1/·Tg2576, 58.4 8.1 s, n 10]. Percent inves-
have both below-normal cerebral A levels and impairedtigation time during the second exposure trial relative
spontaneous alternation performance in the Y mazeto the first trial was significantly different between the
(Figure 1B), although BACE1 null mutation does not af-groups [F(3,64)4.07, p0.01]. Post hoc Fisher’s PLSD
fect social recognition memory (Figure 1A).test revealed that social recognition memory, which was
assessed by exposing the mice to the same juvenile 3
hr later, was significantly impaired in Tg2576 mice (p Rescue of Hippocampal Cholinergic Dysfunction
in BACE1/·Tg2576 Mice0.01) (Figure 1A). Interestingly, BACE1/·Tg2576 bi-
genic mice performed significantly better than did We next conducted hippocampal slice electrophysiol-
ogy to elucidate the cellular mechanism by which theTg2576 mice (p  0.05) and were equivalent to wild-
type littermates in this social recognition task. BACE1 null mutation rescues hippocampus-dependent
learning and memory deficits in Tg2576 mice. RecentNext, we tested memory with another hippocampus-
dependent learning task, spontaneous alternation in the evidence suggests that low concentrations of exoge-
nously applied A can inhibit cholinergic signal trans-Y maze (Lalonde, 2002), which is relatively sensitive to
early-onset cognitive deficits in Tg2576 mice (Holcomb duction independent of apparent neurotoxicity (Auld et
al., 1998; Huang et al., 2000; Kelly et al., 1996). Thiset al., 1998, 1999). ANOVA revealed significant differences
in percent alternation between the groups [F(3,68) 6.85, property of A may contribute to the vulnerability of
cholinergic neuronal populations in AD and to the earlyp  0.01]. Consistent with previous reports (Holcomb
et al., 1998, 1999), Tg2576mice showed reduced spon- phases of cognitive impairment that we observe in
4- to 6-month-old Tg2576 mice. In fact, recent evidencetaneous alternation performance in the Y maze at 4–6
months (p 0.01) (Figure 1B), an age before substantial demonstrates that cholinergic activation of protein ki-
nase C and modulation of GABA transmission are im-A deposition is apparent (Kawarabayashi et al., 2001).
Importantly, the spatial working memory deficit in the Y paired by 2 months of age in cortical neurons of Tg2576
mice (Zhong et al., 2003). These findings prompted usmaze test was rescued to wild-type control level in the
Memory Benefits of BACE1 KO in APP Transgenic Mice
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Figure 1. BACE1 Null Mutation Rescues
Memory Deficits in the Tg2576 Alzheimer’s
Model
(A) Social recognition memory assessed with
a 3 hr intertrial delay (n 10–20). The amount
of investigation time during the second expo-
sure to the same juvenile mouse divided by
that of the initial investigation time  100 (%
investigation) was used as an index of social
recognition memory. Note that only the
Tg2576 group does not show a reduction in
spontaneous investigation to a familiar juve-
nile (approximately 100%) and thus is signifi-
cantly impaired in this hippocampus-depen-
dent test.
(B) Spontaneous alternation Y maze perfor-
mance for the measurement of spatial work-
ing memory (n  12–21). Tg2576 mice per-
form poorly (only slightly above 50% chance
levels) in the Y maze test as compared to
wild-type control and BACE1/·Tg2576 mice. BACE1/ mice are moderately but significantly impaired.
(C) Total number of arm entries reflecting exploratory activity in the Y maze (n  12–21). Note that both BACE1/ and BACE1/·Tg2576
mice explore more than wild-type mice.
Each column represents the mean  SEM. Significant differences from wild-type group (*p  0.05, **p  0.01) and Tg2576 group (#p  0.05,
##p  0.01), compared by ANOVA and post hoc Fisher’s PLSD test.
to test the possibility that cholinergic dysfunction con- bigenic mice was restored to wild-type control level
(p  0.05) (Figures 2A–2C). In addition, the effects oftributes to the memory deficits of Tg2576 mice and
that improved cholinergic function may underlie the res- carbachol on sAHP of BACE1/ monogenic CA1 pyra-
midal cells were similar to those of wild-type cells, sug-cue of memory in BACE1/·Tg2576 mice.
Increased hippocampal neuronal excitability, as as- gesting that the poor performance of BACE1/ mice in
the Y maze is not due to cholinergic dysfunction in thesessed by a reduction in post-burst afterhyperpolariza-
tion (AHP), is known to be a cellular consequence of hippocampus. Overall, our findings demonstrate that
BACE1 deficiency and reduced A levels rescue hippo-learning and is acetylcholine dependent (Saar et al.,
2001; Wu et al., 2002). We measured the suppression campal learning and memory deficits in the Tg2576 Alz-
heimer’s model, at least in part, by correcting impairedof the AHP in CA1 pyramidal neurons following applica-
tion of the cholinergic receptor agonist carbachol. While cholinergic regulation of hippocampal neuronal excit-
ability.carbachol at 0.5 	M did not affect the peak amplitude
of the AHP, it significantly increased neuronal excitabil-
ity by inhibiting the slow component of the AHP (sAHP)
Discussion(Figure 2A). Significant differences between groups
were found in the effects of carbachol on sAHP as mea-
Considerable advances have been made toward antiam-sured by decreases in amplitudes at 1 s after pulse
yloid therapies. For example, recent studies demon-offset [F(3,31)  3.34, p  0.05] (Figure 2B). We also
strate that A immunotherapy reduces amyloid pathol-assessed sAHP by calculating the integrated area from
ogy and slows cognitive decline in some AD patients,0.3 s to 4.8 s (the end of recording) (Figure 2C), and
although adverse symptoms consistent with meningo-reduction of the sAHP area following carbachol applica-
encephalitis were reported in a subset of patients (Hocktion was also significantly different between groups
et al., 2003; Nicoll et al., 2003). Clearly, much work re-[F(3,31)  3.40, p  0.05]. For both sAHP measures,
mains for the identification, validation, and practical ap-carbachol-induced increases in neuronal excitability, an
plication of therapeutic approaches that are truly dis-in vitro model of learning and memory, was significantly
ease modifying and improve AD-associated cognitiveimpaired in hippocampal slices from Tg2576 mice (p
deficits. Our combined use of behavioral, biochemical,0.05). Notably, cholinergic stimulation of neuronal excit-
and electrophysiological methods to analyze BACE1ability of CA1 pyramidal cells from BACE1/·Tg2576
knockout mice engineered to overexpress human APP
(BACE1/·Tg2576) has provided compelling evidence
for the therapeutic potential of -secretase inhibitionTable 1. BACE1 Null Mutation Blocks Cerebral A Generation
for treating memory impairment in AD. We used social
Genotype n A40 (%) A42 (%) recognition and spontaneous alternation Y maze tasks,
Wild-type 7 3.31  0.35 4.80  0.37 which are nonaversive paradigms that rely on natural
BACE1/ 7 0.42  0.04 1.35  0.03 social and exploratory behavior of mice (Ferguson et
Tg2576 7 100  6.23 100  8.36 al., 2002; Lalonde, 2002). The present study clearly dem-
BACE1/·Tg2576 5 1.07  0.11 5.13  0.18
onstrates that BACE1 deficiency rescues the memory
Levels of A40 and A42 were quantified by sandwich ELISA assays deficits of the Tg2576 Alzheimer’s model in the two dif-
after behavioral tests were completed. Values are the mean (SEM) ferent hippocampus-dependent learning tasks. The re-
expressed as percent, where 100% is Tg2576.
duction of cerebral A, especially the more neurotoxic
Neuron
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Figure 2. BACE1 Null Mutation Rescues Hip-
pocampal Cholinergic Dysfunction in the
Tg2576 Alzheimer’s Model
(A) AHP in response to a 100 ms depolarizing
current injection sufficient to elicit a burst of
7 action potentials was recorded from hippo-
campal CA1 pyramidal cells. Representative
traces show the post-burst AHP before (con-
trol) and after the application of 0.5	M carba-
chol (CCh). CCh at 0.5 	M selectively inhibits
the slow component of AHP (sAHP) without
affecting the peak amplitude of AHP. Note
that the effect of CCh on sAHP in Tg2576
neurons is reduced as compared to hippo-
campal neurons from the other three groups.
(B and C) Summary bar graphs showing CCh-
induced reduction in sAHP measured by am-
plitudes at 1 s (B) and by integrated areas
between 0.3 s and 4.8 s (C) after pulse offset.
For both measures, the reduction of Tg2576
sAHP values following CCh application is less
than that of wild-type and BACE1/·
Tg2576. Each column represents the mean  SEM of post-CCh sAHP expressed as % of control (pre-CCh) levels (n  5–10). Significant
differences from wild-type group (*p  0.05) and Tg2576 group (#p  0.05), compared by ANOVA and post hoc Fisher’s PLSD test.
A42, from excessive (Tg2576) to near-normal (BACE1/· may be required for normal memory in this assay. This
result is consistent with recent reports on a potentialTg2576) levels is likely to underlie the memory rescue
in BACE1/·Tg2576 bigenic mice (Figure 3). Thus, our physiological role of A in normal neuronal function (Ka-
menetz et al., 2003; Yu et al., 2001). However, we cannotwork suggests that lowering cerebral A levels through
the therapeutic inhibition of BACE1 should improve exclude the possibility that the absence of proteolytic
products of BACE1 physiological substrates other thanmemory in AD patients.
Interestingly, abrogation of A generation impairs APP, such as sialyltransferase (Kitazume et al., 2001),
may underlie the impaired performance of BACE1/spontaneous alternation performance of BACE1/ sin-
gle mutants in the Y maze (Figure 3), implying that A mice in the Y maze. It should also be noted that
BACE1/ mice are unimpaired in the social recognition
task (Figure 3), demonstrating that BACE1 deficiency
does not affect all types of hippocampal learning. Al-
though further studies will be required to fully character-
ize the behavioral phenotypes of BACE1-deficient mice,
our findings raise the possibility that too much inhibition
of A generation may be deleterious to some forms of
cognition. Nevertheless, this potential issue does not
diminish BACE1 as a therapeutic target, since the dose
of future BACE1 inhibitor drugs could be titrated to allow
low-level A generation to support normal memory
function.
Our results demonstrate electrophysiological abnor-
malities in hippocampal cholinergic function in 4- to
6-month-old Tg2576 mice and are consistent with the
marked cholinergic deficits observed in AD (Coyle et al.,
1983) and the potential link between A peptides and
acetylcholine dysfunction (Auld et al., 1998; Tran et al.,
2002). In particular, our data indicate that cholinergic
stimulation of neuronal excitability following carbachol
application, which is hypothesized to be an in vitro
model of learning and memory (Saar et al., 2001; Wu
et al., 2002), deteriorates significantly in hippocampal
slices from Tg2576 mice. Social recognition and sponta-
Figure 3. Relationship between Cerebral A Levels and Cognitive neous alternation behaviors in mice are disrupted by
Performance pharmacological blockade of muscarinic neurotrans-
Social recognition is impaired by excessive levels of A in Tg2576 mission with scopolamine (Lelong et al., 2003; Winslow
mice but is not affected by ablation of A in BACE1/ mice. In and Camacho, 1995) and by reductions in hippocampal
contrast, spontaneous alternation performance in the Y maze is acetylcholine release during learning (Savage et al.,
sensitive to disruption by both excess (Tg2576) and deficient
2003). Therefore, impaired cholinergic regulation of hip-(BACE1/) levels of cerebral A. Importantly, BACE1/·Tg2576
pocampal neurons is likely to contribute to memory defi-bigenic mice are unimpaired in both hippocampal learning tasks,
most likely because brain A levels have been restored to normal. cits in Tg2576 mice. Importantly, carbachol-induced in-
Memory Benefits of BACE1 KO in APP Transgenic Mice
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creases in excitability are restored to wild-type control including a recently introduced triple-transgenic model
level in hippocampal neurons of BACE1/·Tg2576 that develops A and tau-tangle pathology (Oddo et al.,
mice, suggesting that reduction of A levels rescues 2003). The present findings, nevertheless, shed signifi-
cognitive impairment in the bigenic mice, at least in part, cant new light on the relationship between cerebral A
by ameliorating hippocampal cholinergic dysfunction. levels and cognitive function and provide an experimen-
Previous studies comparing APP transgenic versus tal foundation supporting -secretase inhibition for
nontransgenic mice could not unequivocally exclude the AD therapeutics.
possibility that APP overexpression in the brain, rather
Experimental Proceduresthan high cerebral A levels, was the cause of learning
and memory deficits in APP transgenics (Ashe, 2001).
AnimalsHere, we clearly show for the first time that reduction
Mice lacking BACE1 (BACE1/) with the BlkSw/129 background
of cerebral A levels by genetic ablation of BACE1 pre- (Amgen Inc.) (Luo et al., 2001) were bred to mice transgenic for
vents memory deficits and hippocampal neuronal ab- human APP-695 with the “Swedish” mutation (Tg2576) with the
normalities in Tg2576 mice, despite massive APP over- B6/SJL background (Taconic Farms Inc.) (Hsiao et al., 1996). The
resultant F1 progeny were intercrossed, yielding animals with theexpression in the brain. These results provide a rigorous
genotypes of interest. Genotyping was performed by PCR analysistest of the amyloid cascade hypothesis in vivo and
of tail DNA. All experiments were done with a subset of the F2indicate that A is the primary cause of cognitive and
progeny and carried out blind with respect to the genotype of thehippocampal cholinergic impairments in the Tg2576 Alz-
mice. The mice from each genotype were age-matched littermates.
heimer’s model. Furthermore, the behavioral and elec- The crossbreeding between BACE1 knockout mice and Tg2576 mice
trophysiological abnormalities of the Tg2576, and the was done at Northwestern University, and the experiments were
rescue of BACE1/·Tg2576, were observed months conducted with the approval of the Northwestern University Animal
Care and Use Committee.before the start of amyloid deposition, indicating that
soluble A assemblies may be detrimental. It is relevant
Social Recognition Taskto note a recent study in which a single systemic injec-
The basic protocol for the social recognition experiments has beention of anti-A antibody into PDAPP transgenic mice
described previously (Kogan et al., 2000). Each mutant or wild-type
rapidly reversed cognitive deficits, as assessed by an littermate mouse to be tested was placed into a clean acrylic cage
object recognition task, presumably by sequestering (the same plastic cage used for housing, 27 cm long 16 cm wide
soluble A without affecting A deposits (Dodart et al., 12 cm high). Immediately, a male juvenile CD1 mouse (3- to 4-weeks-
old) was placed into the cage with a test mouse for an initial interac-2002). Our findings are consistent with this conclusion
tion trial of 2 min. Following a 3 hr intertrial delay, the same juvenileand suggest that soluble, as opposed to deposited, A
was placed back into the test mouse’s cage for a 2 min test trial.assemblies are likely to be responsible for disrupting
Social investigation of the juvenile by the test mouse was observed
learning and memory in APP transgenic mice. continuously and time-sampled by an experimenter. Social investi-
Since BACE1-deficient mice lack, in addition to A, gation behavior includes direct contact with the juvenile while in-
the -secretase-cleaved C-terminal fragment (-CTF) specting any part of the body surface (grooming, licking, and paw-
ing), sniffing of the mouth, ears, tail, and ano-genital area, and closeand secreted ectodomain (APPs) (Luo et al., 2001), we
following (1 cm) of the juvenile. Since juvenile males provide rela-cannot exclude the possibility that some components
tively neutral stimulus value, they tend to provoke minimal amountsof behavioral impairment in Tg2576 mice may involve
of fighting and sexual behavior from the resident adult subjects.these APP fragments. In particular, accumulation of the
Nevertheless, given any aggressive encounter between animals, the
potentially amyloidogenic -CTF may contribute to cog- experiment was terminated immediately and the data excluded from
nitive decline (Nalbantoglu et al., 1997; Suh, 1997). In analysis. The duration of investigation time during the second expo-
this regard, it is important to note a recent finding that sure divided by the initial investigation time  100 (% investigation)
was used to measure social recognition memory.neuron-specific, postnatal deficiency of presenilin-1 (the
active-site component of -secretase) and consequent
Spontaneous Alternation Y maze Taskdecrease of cerebral A levels fail to rescue cognitive
Spontaneous alternation was tested as described previously (Hol-defects, as assessed by an object recognition test, in
comb et al., 1998). This learning task does not involve any training,APP[V717I] transgenic mice (Dewachter et al., 2002).
reward, or punishment and allows us to assess spatial working
This study suggests that -CTF accumulation in the memory that is dependent upon the hippocampus. The symmetrical
brain due to -secretase inactivation has detrimental Y maze made of acrylic consists of three arms separated by 120
effects that mask or interfere with any benefit that may degrees. Each arm is 40 cm long, 17 cm high, 4 cm wide at the bottom
and 13 cm wide at the top. Each mouse was placed in the centerhave accrued by lowering A levels. In our study, BACE1
of the Y maze and was allowed to explore freely through the mazedeficiency is beneficial for memory in the Tg2576 Alzhei-
during an 8 min session. The sequence and total number of armsmer’s model possibly by preventing both A and -CTF
entered was recorded. Arm entry was considered to be completedgeneration (Luo et al., 2001), although further investiga- when the hind paws of the mouse had been completely placed in
tion is required. the arm. Percentage alternation is the number of triads containing
In conclusion, our data provide the first demonstration entries into all three arms divided by the maximum possible alterna-
that genetic inhibition of BACE1 can rescue memory tions (the total number of arms entered minus 2)  100.
deficits in an AD animal model by lowering brain A
ELISA Quantitation of Brain A Levelslevels and correcting hippocampal cholinergic dysfunc-
After behavioral tests were completed, Awas measured essentiallytion. Thus, our work validates the development of
as described previously (Duff et al., 1996; Miller et al., 2003). Frozen-secretase inhibitors for the treatment of cognitive im-
hemibrains were extracted in 0.2% diethylamine in 50 mM NaCl and
pairment in AD. Given that no mouse model fully recapit- centrifuged at 20,000 g for 1 hr at 4
C to remove insoluble material.
ulates the entire neuropathological spectrum of AD Supernatant fractions were analyzed by sandwich ELISA using the
(Wong et al., 2002), it will be important to test the impact well-characterized BNT77/BA27 and BNT77/BC05 antibody sys-
tems to detect A40 and A42, respectively. These sandwich ELISAsof BACE1 deficiency with different Alzheimer’s models,
Neuron
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recognize both human and mouse A40 and A42 with equivalent ease: a disorder of cortical cholinergic innervation. Science 219,
1184–1190.sensitivity.
Dewachter, I., Reverse, D., Caluwaerts, N., Ris, L., Kuiperi, C., Van
Electrophysiology Den Haute, C., Spittaels, K., Umans, L., Serneels, L., Thiry, E., et al.
Intracellular recordings were made from CA1 pyramidal neurons of (2002). Neuronal deficiency of presenilin 1 Inhibits amyloid plaque
mouse hippocampal slices as described previously (Colling et al., formation and corrects hippocampal long-term potentiation but not
1996; Mallucci et al., 2002). Transverse hippocampal slices (300 	m a cognitive defect of amyloid precursor protein [V717I] transgenic
thick) were prepared and then maintained in an artificial cerebral mice. J. Neurosci. 22, 3445–3453.
spinal fluid (aCSF)-filled holding chamber at 36
C for at least 1 hr. Dineley, K.T., Xia, X., Bui, D., Sweatt, J.D., and Zheng, H. (2002).
The aCSF contained (in mM) 124 NaCl, 3 KCl, 2.4 CaCl2, 2.0 MgCl2, Accelerated plaque accumulation, associative learning deficits, and
1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose. Slices were trans- up-regulation of 7 nicotinic receptor protein in transgenic mice
ferred to the submerged glass-bottom recording chamber mounted co-expressing mutant human presenilin 1 and amyloid precursor
onto the stage of an upright microscope (DM-LFS, Leica Microsys- proteins. J. Biol. Chem. 277, 22768–22780.
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